CAJ | 학술논문

背景与目的：SERPINA3是丝氨酸蛋白酶抑制剂超家族的一员，已有研究证实其在多种肿瘤细胞中异常表达。然而，它在子宫内膜癌中生物学功能及临床意义尚不清楚。本研究旨在探讨SERPINA3在子宫内膜癌细胞中的功能和子宫内膜癌预后评估中的价值。方法：①收集20对子宫内膜癌组织和正常子宫内膜组织，用实时定量PCR(quantitative real-time PCR)检测SERPINA3 mRNA在内膜组织中表达情况；②使用免疫组化方法，检测组织芯片(子宫内膜癌81例和正常对照37例)的SERPINA3表达情况，依据染色结果，用SPSS软件分析SERPINA3与子宫内膜癌临床病理特征之间的关系；③检测5株子宫内膜癌细胞系中SERPINA3的表达情况，选取表达量最高的HEC-1A细胞，利用小片段干扰RNA(small interfering RNA)干扰SERPINA3基因在HEC-1A细胞中的表达；④蛋白质印迹法(Western blot)和qPCR检测干扰后HEC-1A中SERPINA3基因在mRNA和蛋白水平表达情况，细胞迁移实验检测细胞运动能力的变化。结果：①SERPINA3 mRNA在内膜癌中表达明显高于对照内膜组织(n=20，P<0.05)；②免疫组化结果显示SERPINA3在子宫内膜癌中的表达水平高于正常子宫内膜组织(P<0.001)。SERPINA3的表达水平与子宫内膜癌的临床分期、肿瘤细胞级别、脉管浸润、淋巴结转移之间比较差异有统计学意义(P<0.05)；③干扰SERPINA3组细胞迁移能力显著减弱。结论：SERPINA3基因在子宫内膜癌中表达显著上调，可能与子宫内膜癌的侵袭和转移等相关。SERPINA3有望成为评估子宫内膜癌预后的生物学标志物，并可能作为子宫内膜癌生物靶向治疗的靶标之一。
배경여목적：SERPINA3시사안산단백매억제제초가족적일원，이유연구증실기재다충종류세포중이상표체。연이，타재자궁내막암중생물학공능급림상의의상불청초。본연구지재탐토SERPINA3재자궁내막암세포중적공능화자궁내막암예후평고중적개치。방법：①수집20대자궁내막암조직화정상자궁내막조직，용실시정량PCR(quantitative real-time PCR)검측SERPINA3 mRNA재내막조직중표체정황；②사용면역조화방법，검측조직심편(자궁내막암81례화정상대조37례)적SERPINA3표체정황，의거염색결과，용SPSS연건분석SERPINA3여자궁내막암림상병리특정지간적관계；③검측5주자궁내막암세포계중SERPINA3적표체정황，선취표체량최고적HEC-1A세포，이용소편단간우RNA(small interfering RNA)간우SERPINA3기인재HEC-1A세포중적표체；④단백질인적법(Western blot)화qPCR검측간우후HEC-1A중SERPINA3기인재mRNA화단백수평표체정황，세포천이실험검측세포운동능력적변화。결과：①SERPINA3 mRNA재내막암중표체명현고우대조내막조직(n=20，P<0.05)；②면역조화결과현시SERPINA3재자궁내막암중적표체수평고우정상자궁내막조직(P<0.001)。SERPINA3적표체수평여자궁내막암적림상분기、종류세포급별、맥관침윤、림파결전이지간비교차이유통계학의의(P<0.05)；③간우SERPINA3조세포천이능력현저감약。결론：SERPINA3기인재자궁내막암중표체현저상조，가능여자궁내막암적침습화전이등상관。SERPINA3유망성위평고자궁내막암예후적생물학표지물，병가능작위자궁내막암생물파향치료적파표지일。
Background and purpose: SERPINA3 is a protease inhibitor, belonging to the serpin super family. It has been reported that SERPINA3 expression up-regulated in various tumor cells. However, its clinical signif-icance and biological function in endometrial cancer remains unclear. This study was aimed to investigate the effect and prognosis value of up-regulated SERPINA3 (α1-ACT) in endometrial cancer.Methods:①We collected 20 pairs of en-dometrial carcinoma and normal endometrial tissues then extracted total RNA, detected SERPINA3 mRNA expression by quantitative real-time PCR;②Immunohistochemistry was used to detect the expression of SERPINA3 in tissue chip which contained 81 endometrial cancer tissue samples and 37 normal controls endometrial tissues, based on the results, using SPSS software to analyze the relationship between SERPINA3 expression with clinicopathological features of endometrial cancer;③The highest SERPINA3 expression was selected from 5 endometrial cancer cells, then small interfering RNA targeted interference SERPINA3 gene expression;④With real-time quantitative PCR and Western blot methods, we detected SERPINA3 gene expression in mRNA and protein levels after interference, at last, analyzed cell motility by cell migration assay. Results:①SERPINA3 mRNA expression in endometrial carcinoma was signiifcantly higher than the control endometrial tissue (n=20, P<0.05);②Immunohistochemistry also showed SERPINA3 expres-sion in endometrial carcinoma higher than in normal endometrial tissues (P<0.001). The analysis showed that between the expression level of SERPINA3 with endometrial cancer clinical stage, tumor differentiation, vascular invasion, lymph node metastasis, there was a close correlation (P<0.05);③Interference expression of SERPINA3, endometrial cancer cells migration was signiifcantly reduced. Conclusion:SERPINA3 gene expression in endometrial carcinoma was signiifcantly increased and correlated with endometrial cancer invasion and metastasis;SERPINA3 is expected to become the pathological marker of diagnosis and determination in the prognosis of endometrial cancer. It may be used as one of the biological target of endometrial cancer targeted therapy.